Optimmun eye ointment 3.5g

DESCRIPTION

Optimmune is an eye ointment for the treatment of autoimmune eye diseases in dogs.

COMPOSITION

Optimmun as an active ingredient in 1 g contains 2.0 mg of cyclosporin A, and as auxiliary substances: white soft paraffin - 551.7 mg, corn oil - 426.3 mg, amerhol - 20.0 mg.

PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group of the drug: immunosuppressive drugs.

Cyclosporin A, which is part of the drug, is a cyclic polypeptide produced by the fungi Tolypocladium inflatum gans. It is an immunosuppressive agent with anti-inflammatory and lacrimomimetic action.

The immunosuppressive and anti-inflammatory effect of cyclosporin A is associated with blocking at the cellular level resting lymphocytes in the GO or G1 phases of the cell cycle and suppressing antigen-triggered production and secretion of cytokines (including interleukin-2, a T-lymphocyte growth factor) activated by T-lymphocytes. Cyclosporine acts reversibly on lymphocytes.

Due to this, the function of the acinar cells of the secretory epithelium of the lacrimal gland is restored and the infiltration of the eye tissues decreases. As a result of the anti-inflammatory effect, the condition of the surface of the affected eye improves: conjunctival hyperplasia decreases, with prolonged use, neovascularization and corneal pigmentation decrease.

In addition to immunosuppressive activity, cyclosporin A has a direct lacrimomimetic effect, blocking the suppression of tear production by prolactin. Thus, the increase in lacrimation under the influence of Optimmun is identical to the natural one.

Cyclosporin A is highly lipophilic and penetrates well into the cornea and the lacrimal gland. Cyclosporin A is deposited in the cornea, weakly penetrates into the internal environment of the eye and is practically not absorbed into the bloodstream, without exerting a systemic effect on the body.

According to the degree of impact on the body, Optimmun belongs to low-hazard substances (hazard class 4 according to GOST 12.1.007-76).

INDICATIONS

Optimmun is used for the treatment of eye diseases of autoimmune etiology in dogs: idiopathic keratoconjunctivitis dry (SCC), plasma infiltration of the third eyelid and chronic superficial keratitis (pannus).

The drug can be used to enhance the effect of topical corticosteroids or instead of them if corticosteroids are contraindicated due to corneal ulceration.

DOSAGE AND APPLICATION

Before applying the ointment, the affected eye is washed and thoroughly cleansed. A small amount of ointment (1 / 2-1 cm) is applied directly to the cornea or into the conjunctival sac every 12 hours, without touching the tip of the tube to the surface of the eye.

An increase in tear production is expected within 10 days after starting the drug, but it can take up to 6 weeks to reach the maximum tear production. In the treatment of keratoconjunctivitis dry, it is recommended to evaluate the effectiveness of therapy using the Schirmer test. For correct interpretation of the results, the Schirmer test is recommended to be performed 3 hours after the application of Optimum, when the concentration of cyclosporine in the cornea is maximum. The best results of treatment can be achieved with the use of Optimmun in the early stages of the SSC, when there was no irreversible damage and fibrosis of the lacrimal gland tissues. The duration of therapy depends on the severity of the lesion and the response to treatment. In most cases of BCC and pannus, dogs require lifelong treatment.

With pannus, due to the influence of environmental factors (such as ultraviolet light) on pathogenesis, the need to use Optimmun may decrease during periods of reduced solar activity, and during an exacerbation of the disease, the use of Optimmun is resumed.

Long-term therapy with Optimmunum does not increase the susceptibility of the eye to microbial infections.

SPECIAL INSTRUCTIONS

Overdose symptoms with the use of the drug were not identified.

In the first days of using Optimmun, slight irritation is possible, if irritation persists, the use of the drug is stopped. In the event of allergic reactions, the use of Optimmun is stopped and symptomatic therapy is carried out.

Avoid gaps in the introduction of the next dose of the drug, as this can lead to a decrease in therapeutic efficacy. Continuity is important in the treatment of BSC, and studies have shown that stimulation of tear production ceases within 24 hours of stopping therapy. If you miss one dose, you must enter it as soon as possible. Further, the interval between drug injections does not change.

Optimum is not intended for use in productive animals.

CONTRAINDICATIONS

Optimum should not be used for fungal and viral eye infections.

SIDE EFFECTS

In rare cases, there is inflammation and swelling of the eyelid skin caused by an excessive amount of ointment. In this case, the dose of the applied drug should be reduced.

SHELF LIFE AND STORAGE

Optimmun is stored in a sealed manufacturer's packaging, in a dry place protected from direct sunlight, separately from food and feed, at a temperature from 2 В° C to 25 В° C.

The shelf life of the medicinal product, subject to storage conditions, is 2 years from the date of manufacture, after opening the package - 28 days. It is forbidden to use the medicinal product after the expiration date.

PACKAGING

Optimum is packaged in aluminum tubes with a white polyethylene tip and screw cap. Tubes are packed in individual cardboard boxes.

Specifications

KolVUP

ten

Manufacturer

Intervet

Temperature regime

from +2 to +25

Teaser

ointment for the treatment of eye diseases of autoimmune etiology in dogs, idiopathic keratoconjunctivitis dry, plasma infiltration of the third eyelid and chronic superficial keratitis